Amgen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

11.12.06	Updated Interim Long-Term Follow-up Data Reported AMG 531 Dosed Once Weekly Increased and Sustained Platelet Counts in Patients with Immune Platelet Disorder (Businesswire)
09.12.06	Data Show Efficacy of Extended Dosing of Aranesp(R) in the Treatment of Chemotherapy-Induced Anemia (Businesswire)
12.11.06	ENBREL is the First Biologic to Publish Data Showing Safety and Sustained Efficacy for up to Nine Years in Patients with Moderate-to-Severe Rheumatoid Arthritis (Businesswire)
04.11.06	AMG 706 Shows Activity in Phase 2 Study of Patients with Advanced Imatinib-Resistant Gastrointestinal Stromal Tumors (Businesswire)
02.11.06	Nominations Open for the Amgen Award for Science Teaching Excellence (Businesswire)
07.09.06	Amgen Launches Aranesp(R) (Darbepoetin Alfa) Prefilled SureClick(TM) Autoinjector for Treatment of Anemia Associated with Chemotherapy and Chronic Kidney Disease (Businesswire)
21.07.06	Wall Street Update: Schwacher Mittagshandel, Dell und AMD brechen ein (Aktiencheck)
20.07.06	Wichtige US-Quartalszahlen vom 20.07.2006 (Aktiencheck)
16.07.06	New Data Demonstrate Benefits of Aranesp(R) Dosed Every Two Weeks in European Haemodialysis Patients With CKD-Related Anaemia (Businesswire)
07.07.06	ITC Judge Grants Summary Determination That Roche's Activities Are Covered by Clinical Trial Exemption; Judge's Decision Does Not Address the Merits of Roche's Infringement of Amgen's Patents (Businesswire)
04.06.06	Phase 2 Interim Data Show Denosumab Decreased Bone Turnover in Advanced Cancer Patients with Bone Metastases (Businesswire)
09.05.06	ITC Accepts Amgen's Complaint to Investigate Roche's Importation of Peg-EPO (Businesswire)
19.04.06	Ausblick: Die Märkte am Mittwoch (n/a)
10.04.06	2006 Recipients of Amgen Award for Science Teaching Excellence Announced; 19 Outstanding Science Teachers and Their Schools Recognized in Amgen Communities Across the U.S. and Puerto Rico (Businesswire)
04.04.06	Amgen schliesst Kauf von Abgenix ab; durch den Erwerb wird Panitumumab vollständiges Eigentum von Amgen und eine Denosumab-Lizenzgebührenzahlung entfällt (Businesswire)
22.02.06	Investigational Therapy Denosumab Increased Bone Mineral Density with Twice-Yearly Dosing; One Year Data Published in New England Journal of Medicine (Businesswire)
26.01.06	TecDAX Schluss: Fortsetzung der Kursrallye, EPCOS an der Spitze (n/a)
25.01.06	Amgen investiert umfangreich in Fertigung, Forschung und Entwicklung und den Ausbau des Vertriebs (Businesswire)
15.12.05	Amgen will Abgenix für 2,2 Mrd. Dollar übernehmen, Abgenix-Aktie +50 Prozent (n/a)
14.12.05	Amgen to Acquire Abgenix for $22.50 Per Share; Provides Amgen With Full Ownership of Panitumumab and Eliminates a Denosumab Royalty (Businesswire)
14.11.05	Two-Year Trial Results of Amgen Investigational Therapy for Bone Loss, Denosumab, Show Increased Bone Mineral Density with Twice-Yearly Dosing (Businesswire)
14.11.05	Treatment Has Demonstrated Improvement in Physical Function and Kept Joint Damage from Progressing at Three Years (Businesswire)
03.11.05	Panitumumab Significantly Improves Progression-Free Survival in Phase 3 Randomized Metastatic Colorectal Cancer Study (Businesswire)
28.10.05	European Commission Approves Kepivance(TM) (Palifermin) for Oral Mucositis in Cancer Patients Undergoing Blood and Bone Marrow Transplant (Businesswire)
20.10.05	Wall Street: Fest, Pfizer und Ford enttäuschen (n/a)
19.10.05	Amgen's Third Quarter 2005 Adjusted Earnings Per Share Increased 33 Percent to 85 Cents; Third Quarter 2005 GAAP Earnings Per Share Increased to 77 Cents from 18 Cents (Businesswire)
15.09.05	FDA Expands Neulasta(R) Label; New Label Extends First-Cycle Protection From Infection To Cancer Patients Receiving Moderately Myelosuppressive Chemotherapy (Businesswire)
02.09.05	Amgen Names Phyllis Piano Vice President, Corporate Communications and Philanthropy (Businesswire)
02.09.05	Amgen Announces Initiation of Phase 3 Trial to Evaluate the Impact of Treating Anemia with Darbepoetin Alfa in Patients with Heart Failure to Reduce Mortality and Hospitalization (Businesswire)
10.08.05	Amgen Names Michael Kelly as Chief Accounting Officer (Businesswire)
01.08.05	Abgenix and Amgen Announce FDA Grants Panitumumab Fast Track Designation for Metastatic Colorectal Cancer (Businesswire)
22.07.05	Börse Stuttgart-Kolumne: Marktbericht Auslandsaktien (KW 29) (n/a)
15.05.05	Final Results of Phase 3 Head-to-Head Study Demonstrate Aranesp Dosed (Businesswire)
15.05.05	Large Community-Based Clinical Trial in Older Cancer Patients Suggests (Businesswire)
15.05.05	Aranesp Dosed Every Three Weeks Achieved and Maintained Target Hemoglo (Businesswire)
06.05.05	Amgen Submits Supplemental Biologics License Application for Aranesp E (Businesswire)
05.05.05	Amgen Announces One-Day Extension of Its Exchange Offer for Its Outsta (Businesswire)
03.05.05	Amgen Announces Plans to Webcast Selected Management Presentations (Businesswire)
21.04.05	Amgen's First Quarter 2005 Adjusted Earnings Per Share Increased 26 P (Businesswire)
04.04.05	Amgen Announces Webcast of First Quarter Financial Results (Businesswire)
28.03.05	Landmark Trial Will Evaluate the Impact of Treating Anemia on Cardiova (Businesswire)
25.02.05	Phase 3 Study Published in The Journal of Clinical Oncology Shows Firs (Businesswire)
11.02.05	Following Complete Review of Phase 2 Trial Data Amgen Confirms Decisio (Businesswire)
31.01.05	Amgen Announces Put Option Notification for Liquid Yield Option Notes (Businesswire)
27.01.05	Amgen's Fourth Quarter 2004 Adjusted Earnings Per Share Increased 26 (Businesswire)
27.01.05	Wichtige US-Quartalszahlen vom 27.01.2005 (n/a)
22.01.05	Amgen Announces Webcast of 2004 Fourth Quarter and Full Year Financial (Businesswire)
11.01.05	Amgen Significantly Expands Support of Patient Assistance Programs; Fi (Businesswire)
04.01.05	Amgen Donates $1 Million and Establishes Tsunami Relief Program; Staff (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	53.56	3.72 %	K V
Sonova Hldg	318.50	3.11 %	K V
Part Grp Hldg	1’381.00	2.30 %	K V
Alcon	80.90	1.81 %	K V
Lonza Grp	580.40	1.79 %	K V
Nestle	74.18	-0.75 %	K V
Geberit	500.80	-0.91 %	K V
Kuehne+Nagel Int	204.60	-1.06 %	K V
Swisscom	506.50	-1.65 %	K V
Logitech Intl	79.90	-1.75 %	K V

mehr

17:58		Freundlicher Handel: Euro STOXX 50 zum Handelsende mit grünem Vorzeichen
17:58		Freundlicher Handel in Frankfurt: LUS-DAX letztendlich stärker
17:58		Zuversicht in Frankfurt: DAX verbucht schlussendlich Zuschläge
15:58		Zuversicht in Europa: Anleger lassen Euro STOXX 50 am Nachmittag steigen
15:58		Aufschläge in Frankfurt: DAX am Nachmittag in der Gewinnzone
15:58		Börse Frankfurt in Grün: LUS-DAX legt zu
12:26		Pluszeichen in Frankfurt: LUS-DAX mittags in der Gewinnzone
12:26		Optimismus in Europa: Euro STOXX 50 am Mittag mit grünem Vorzeichen

17:58

Freundlicher Handel: Euro STOXX 50 zum Handelsende mit grünem Vorzeichen

17:58

Freundlicher Handel in Frankfurt: LUS-DAX letztendlich stärker

17:58

Zuversicht in Frankfurt: DAX verbucht schlussendlich Zuschläge

15:58

Zuversicht in Europa: Anleger lassen Euro STOXX 50 am Nachmittag steigen

15:58

Aufschläge in Frankfurt: DAX am Nachmittag in der Gewinnzone

15:58

Börse Frankfurt in Grün: LUS-DAX legt zu